Novel diazabicycloalkane delta opioid agonists

Facile Assembling of Novel 2,3,6,7,9-pentaazabicyclo- [3.3.1]nona-3,7-diene Derivatives under Microwave and Ultrasound Platforms

“…3,7-Diazabicyclo[3.3.1]nonanes are reported to be useful in the treatment of cardiac arrhythmias [16], and exhibited anti-platelet, antithrombotic activities [17], as well as high affinities at various nicotinic acetylcholine receptors (nAChRs) [18,19,20]. 3,9-Diazabicyclo[3.3.1]nonanes showed the 5-HT3 receptor antagonist [21] and opioid δ and μ-receptor activities [22,23]. Triazabicyclo[3.3.1]nonane derivatives such as 2,6,9- and 3,7,9-triazabicyclo[3.3.1]nonanes [24,25,26,27,28] were synthesized from dimerization of α,β-unsaturated carbonyl compounds with alkylamines.…”

“…Some 1,3,5,7-tetraazabicyclo[3.3.1]nonane derivatives have antithrombotic activities [29]. Although tremendous progress has been achieved in the synthesis of mono-, di-, and tri-azabicyclo[3.3.1]nonanes [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27], the synthesis of tetra- and penta-azabicyclo[3.3.1]nonane frameworks has rarely been disclosed in the literature [30,31,32,33].…”